Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation

G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
被引用次数：137 相关文章

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation

G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - 2017 - hero.epa.gov
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or
Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation | Health & Environmental …

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation

G Adeboyeje, G Sylwestrzak… - … of managed care …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The use of non-vitamin K oral anticoagulants (NOACs) has increased steadily
following marketing approval; however, their relative safety in nonvalvular atrial fibrillation …

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.

G Adeboyeje, G Sylwestrzak, JJ Barron… - Journal of Managed …, 2017 - europepmc.org
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban
in Patients with Nonvalvular Atrial Fibrillation. - Abstract - Europe PMC Sign in | Create an …

[引用][C] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation

G Adeboyeje, G Sylwestrzak, JJ Barron… - Journal of Managed …, 2017 - cir.nii.ac.jp
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or
Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation | CiNii Research CiNii 国立情報学 …
[HTML] nih.gov

[HTML][HTML] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation

G Adeboyeje, G Sylwestrzak, JJ Barron… - Journal of Managed …, 2017 - ncbi.nlm.nih.gov
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …